Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

macleods pharmaceuticals limited - pioglitazone hydrochloride (unii: jqt35npk6c) (pioglitazone - unii:x4ov71u42s) - pioglitazone 15 mg - monotherapy and combination therapy pioglitazone tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings [see clinical studies (14)  ] . important limitations of use pioglitazone tablets, usp exerts its antihyperglycemic effect only in the presence of endogenous insulin. pioglitazone tablets usp should not be used to treat type 1 diabetes or diabetic ketoacidosis, as it would not be effective in these settings. use caution in patients with liver disease [see warnings and precautions (5.3) ]. • initiation in patients with established new york heart association (nyha) class iii or iv heart failure [see boxed warning]. (4) • use in patients with known hypersensitivity to pioglitazone or any other component of pioglitazone hydrochloride.(4) risk summary limited data with pioglitazone hydrochloride in pregnant women are not sufficient to determine a drug-associated risk for major birth defects or misca

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

teva pharmaceuticals usa - pioglitazone hydrochloride (unii: jqt35npk6c) (pioglitazone - unii:x4ov71u42s) - pioglitazone 15 mg

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

prasco laboratories - pioglitazone hydrochloride (unii: jqt35npk6c) (pioglitazone - unii:x4ov71u42s), glimepiride (unii: 6ky687524k) (glimepiride - unii:6ky687524k) - pioglitazone 30 mg - pioglitazone and glimepiride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with a thiazolidinedione and sulfonylurea or who have inadequate glycemic control on a thiazolidinedione alone or a sulfonylurea alone [see clinical studies (14)] . important limitations of use pioglitazone exerts its antihyperglycemic effect only in the presence of endogenous insulin. pioglitazone and glimepiride tablets should not be used to treat type 1 diabetes or diabetic ketoacidosis, as it would not be effective in these settings. use caution in patients with liver disease [see warnings and precautions (5.5)]. - initiation in patients with established nyha class iii or iv heart failure [see boxed warning] . - use in patients with known hypersensitivity to pioglitazone, glimepiride or any other component of pioglitazone and glimepiride tablets [see warnings and precautions (5.3)] . - use in patients with known history of an alle

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - pioglitazone hydrochloride, quantity: 49.608 mg (equivalent: pioglitazone, qty 45 mg) - tablet - excipient ingredients: lactose monohydrate; carmellose calcium; hyprolose; magnesium stearate - treatment of type 2 diabetes inadequately controlled by diet and exercise: ? as monotherapy ? as dual therapy to improve glycaemic control - in combination with metformin or sulfonylurea - in combination with insulin ? as triple therapy to improve glycaemic control - in combination with metformin and sulfonylurea

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - pioglitazone hydrochloride, quantity: 33.072 mg (equivalent: pioglitazone, qty 30 mg) - tablet - excipient ingredients: lactose monohydrate; carmellose calcium; hyprolose; magnesium stearate - treatment of type 2 diabetes inadequately controlled by diet and exercise: ? as monotherapy ? as dual therapy to improve glycaemic control - in combination with metformin or sulfonylurea - in combination with insulin ? as triple therapy to improve glycaemic control - in combination with metformin and sulfonylurea

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - pioglitazone hydrochloride, quantity: 49.608 mg (equivalent: pioglitazone, qty 45 mg) - tablet - excipient ingredients: lactose monohydrate; carmellose calcium; hyprolose; magnesium stearate - treatment of type 2 diabetes inadequately controlled by diet and exercise: ? as monotherapy ? as dual therapy to improve glycaemic control - in combination with metformin or sulfonylurea - in combination with insulin ? as triple therapy to improve glycaemic control - in combination with metformin and sulfonylurea

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - pioglitazone hydrochloride, quantity: 33.072 mg (equivalent: pioglitazone, qty 30 mg) - tablet - excipient ingredients: lactose monohydrate; carmellose calcium; hyprolose; magnesium stearate - treatment of type 2 diabetes inadequately controlled by diet and exercise: ? as monotherapy ? as dual therapy to improve glycaemic control - in combination with metformin or sulfonylurea - in combination with insulin ? as triple therapy to improve glycaemic control - in combination with metformin and sulfonylurea

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - pioglitazone hydrochloride (unii: jqt35npk6c) (pioglitazone - unii:x4ov71u42s) - pioglitazone 45 mg - monotherapy and combination therapy pioglitazone tablets, usp are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings [see clinical studies (14)] . important limitations of use pioglitazone tablets, usp exert its antihyperglycemic effect only in the presence of endogenous insulin. pioglitazone tablets, usp should not be used to treat type 1 diabetes or diabetic ketoacidosis, as it would not be effective in these settings. use caution in patients with liver disease [see warnings and precautions (5.3)] . - initiation in patients with established nyha class iii or iv heart failure [see boxed warning]. - use in patients with known hypersensitivity to pioglitazone or any other component of pioglitazone tablets. teratogenic effects pregnancy category c. there are no adequate and well-controlled studies of pioglitazone in pregnant women. animal studies show increased rates of post-implantation

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

celltrion healthcare australia pty ltd - pioglitazone hydrochloride, quantity: 49.59 mg (equivalent: pioglitazone, qty 45 mg) - tablet, uncoated - excipient ingredients: hyprolose; carmellose calcium; lactose monohydrate; magnesium stearate - treatment of type 2 diabetes mellitus inadequately controlled by diet and exercise: as monotherapy; as dual therapy to improve glycaemic control: in combination with metformin or sulfonylurea; in combination with insulin. as triple therapy to improve glycaemic control: in combination with metformin and sulfonylurea.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

celltrion healthcare australia pty ltd - pioglitazone hydrochloride, quantity: 33.06 mg (equivalent: pioglitazone, qty 30 mg) - tablet, uncoated - excipient ingredients: lactose monohydrate; carmellose calcium; magnesium stearate; hyprolose - treatment of type 2 diabetes mellitus inadequately controlled by diet and exercise: as monotherapy; as dual therapy to improve glycaemic control: in combination with metformin or sulfonylurea; in combination with insulin. as triple therapy to improve glycaemic control: in combination with metformin and sulfonylurea.